SCHEMBL6048435

SCHEMBL6048435

CCC(=O)Oc1ncc[nH]1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.37
ESR1 P03372 2/20 0.37
HIF1A Q16665 2/20 0.37
KMT2A Q03164 2/20 0.37
RECQL P46063 1/20 0.37
HTR1A P08908 2/20 0.37
TAAR1 Q96RJ0 1/20 0.37
ACHE P22303 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
ELANE P08246 1/20 0.34
HTR1D P28221 1/20 0.34
HTR1B P28222 1/20 0.34
MAPT P10636 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
TBXAS1 P24557 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9824924 0.86 ALDH1A1 (0.38) SMN1; SMN2ESR1KMT2AALDH1A1KDM4E
SCHEMBL4060537 0.85 TBXAS1 (0.39) SMN1; SMN2KMT2AALDH1A1KDM4ENPC1
SCHEMBL5060773 0.83 KMT2A (0.41) SMN1; SMN2KMT2ARECQLHTR1AKDM4E
SCHEMBL16859466 0.81 TBXAS1 (0.33) SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A
SCHEMBL11589157 0.81 TBXAS1 (0.44) SMN1; SMN2KMT2AALDH1A1KDM4ENPC1
SCHEMBL25475176 0.81 TBXAS1 (0.33) SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A
SCHEMBL16859448 0.81 TBXAS1 (0.33) SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A
SCHEMBL11048265 0.81 TBXAS1 (0.33) SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A
SCHEMBL16859463 0.81 TBXAS1 (0.33) SMN1; SMN2KMT2AALDH1A1KDM4ENPC1
SCHEMBL9825273 0.81 NPC1 (0.38) SMN1; SMN2ALDH1A1KDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-121528553-B Sepsis myocardial function prognosis prediction method based on imidazole propionic acid targeted intervention Zhoupu Hospital, Pudong New Area, Shanghai (Zhoupu Hospital Affiliated to Shanghai Medical College) (CN) 2026-05-26 CN claimed
US-20260076944-A1 COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH UNIV CALIFORNIA (US) 2026-03-19 US claimed
US-12491217-B2 Compositions and methods for promoting healthy neural development in an unborn baby THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-12-09 US claimed
US-12292445-B2 Methods of selecting subjects for treatment with metabolomic modulators THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-05-06 US claimed
CN-118685743-A Preparation and surface treatment method of high-strength and high-peeling-resistance carrier copper foil 安徽铜冠铜箔集团股份有限公司 2024-09-24 CN claimed
CN-118265532-A Methods and uses of microbiome compositions, components or metabolites for treating neurodegenerative diseases 奇迹生物公司 2024-06-28 CN claimed
CN-118258878-A Blood urine metabolism marker, disease diagnosis and typing system 复旦大学附属中山医院 2024-06-28 CN claimed
CN-117598247-A Application of imidazole propionic acid in preparation of modeling agent for inducing ulcerative colitis animal model 天津中医药大学 2024-02-27 CN claimed
US-20230375534-A1 MEANS AND METHODS TO DIAGNOSE GUT FLORA DYSBIOSIS AND INFLAMMATION VIB VZW (BE) 2023-11-23 US claimed
CN-116990395-A Alzheimer disease biomarker based on feces and application thereof 中国科学院深圳先进技术研究院 2023-11-03 CN claimed
EP-2890808-A2 DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER California Institute of Technology (US) 2015-07-08 EP claimed
US-20140065132-A1 DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER CALIFORNIA INSTITUTE OF TECHNOLOGY 2014-03-06 US claimed
WO-2014036182-A2 DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2014-03-06 WO claimed
JP-3759748-B2 2006-03-29 JP claimed
EP-0736038-B1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK AS (DK) 2001-07-04 EP claimed
CN-1052730-C Compounds with growth hormone releasing properties NOVO NORDISK AS (DK) 2000-05-24 CN claimed
US-5854211-A Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 1998-12-29 US claimed
CN-1138334-A Compounds with growth hormone releasing properties NOVO NORDISK AS (DK) 1996-12-18 CN claimed
EP-0736038-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1996-10-09 EP claimed
WO-1995017422-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1995-06-29 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260076944-A1 COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH IDO1, INMT, IDO2 SMN1; SMN2 1923/4885ESR1 4592/4885HIF1A 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.